Abstract:Background: Genetic testing plays an important role in guiding screening, diagnosis, and precision treatment of breast cancer (BC). However, the appropriate testing criteria for genetic testing remain controversial. The current study aims to facilitate the development of suitable strategies by analyzing the germline mutational profiles and clinicopathological features of large-scale Chinese BC patients.Methods: The clinical data of BC patients who had undergone genetic testing at the Sun Yat-sen University Cancer Center (SYSUCC) from September 2014 to March 2022 were collected. Their distribution and frequency of germline variants in BRCA1/2 testing and 21 genes panel testing were further analyzed.Results: A total of 1,035 BC patients were enrolled, and 237 pathogenic or likely pathogenic variants (P/LPV) were identified in 235 patients, including 41 out of 203 (19.6%) patients tested only for BRCA1/2 genes, and 194 out of 832 (23.3%) received 21 genes panel testing. Among the 235 P/LPV carriers, 222 (94.5%) met the NCCN high-risk criteria, and 13 (5.5%) did not. While using Desai’s criteria of testing all females diagnosed with BC by 60 years and NCCN criteria for older patients, 234 (99.6%) met the high-risk standard, and only one did not. The 21genes panel testing identified 4.9% of non-BRCA P/LPVs and a significantly high rate of VUSs (33.9%). The most common non-BRCA P/LPVs were PALB2 (11, 1.3%), TP53 (10, 1.2%), PTEN (3, 0.4%), CHEK2 (3, 0.4%), ATM (3, 0.4%), BRAD1(3, 0.4%), and RAD51C (2, 0.2%). Compared with BRCA1/2 P/LPVs, non-BRCA P/LPVs showed a significantly low incidence of NCCN criteria listed family history and second primary cancer, and different molecular subtypes.Conclusions: Desai’s criteria might be a more appropriate genetic testing strategy for Chinese BC patients. Panel testing could identify more non-BRCA P/LPVs than BRCA1/2 testing alone. Compared with BRCA1/2 P/LPVs, non-BRCA P/LPVs exhibited different personal and family histories of cancer and molecular subtype distributions. The optimal genetic testing strategy for BC still needs to be investigated with larger continuous population studies.Funding Information: This work was supported by the National Key Research and Development Program (2021YFE0206300), National Natural Science Foundation of China (81773279, 82073391 to Dr. Yanxia Shi), Science and Technology Planning Project of Guangdong Province (2016A050502015, 2013B021800062 and 2012B061700082 to Dr. Yanxia Shi).Declaration of Interests: No potential conflicts of interest were disclosed.Ethics Approval Statement: All patients signed informed consent for genetic testing. The study was approved by the Ethical Committee of SYSUCC and the Ministry of Science and Technology for human genetic resource collection.

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population

Spectrum, prevalence and clinical outcomes of germline mutations in PALB2 genes in 16501 unselected BRCA1/2-negative breast cancer patients: A multi-center analysis

Abstract P2-09-03: Spectrum, Prevalence and Clinical Outcomes of Germline Mutations in PALB2 Genes in 16501 Unselected BRCA1/2-negative Breast Cancer Patients: A Multi-Center Analysis

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

Identification of Recurrent Variants in BRCA1 and BRCA2 Across Multiple Cancers in the Chinese Population

The Prevalence of BRCA1 and BRCA2 Germline Mutations in High-Risk Breast Cancer Patients of Chinese Han Nationality: Two Recurrent Mutations Were Identified

Multicenter Cross-Sectional Screening of the BRCA Gene for Chinese High Hereditary Risk Breast Cancer Populations

Prevalence of <i>BRCA1</i>/<i>BRCA2</i> pathogenic variation in Chinese Han population

Analysis of BRCA1/2 Mutation Spectrum and Prevalence in Unselected Chinese Breast Cancer Patients by Next-Generation Sequencing

Prevalence of BRCA1 and BRCA2 Pathogenic Variants in 8627 Unselected Patients with Breast Cancer: Stratification of Age at Diagnosis, Family History and Molecular Subtype

BRCA Germline Mutations in an Unselected Nationwide Cohort of Chinese Patients with Ovarian Cancer and Healthy Controls

Germline Mutational Profiles and Clinicopathological Features of Hereditary Breast Cancer in Chinese Population

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

Germline Variation In Brca1/2 Is Highly Ethnic-Specific: Evidence From Over 30,000 Chinese Hereditary Breast And Ovarian Cancer Patients

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

BRCA1 and BRCA2 mutations of 140 Chinese breast cancer patients with genetic high risk

Prevalence Of Brca1 And Brca2 Gene Mutations In Chinese Patients With High-Risk Breast Cancer

Gene Panel Sequencing in a Chinese High-risk Breast Cancer Cohort

Prevalence and Spectrum of BRCA Germline Variants in Mainland Chinese Familial Breast and Ovarian Cancer Patients.

The Spectrum of BRCA Mutations and Characteristics of BRCA-associated Breast Cancers in China: Screening of 2,991 Patients and 1,043 Controls by Next-Generation Sequencing.